Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (223)Ra: PARABO, a Prospective, Noninterventional Study

(223)Ra, a targeted α-therapy, is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have bone metastases. In the phase 3 ALSYMPCA study, (223)Ra prolonged survival and improved quality of life versus placebo. Our real-world study, PARABO, investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmedo, Holger, Ahmadzadehfar, Hojjat, Eschmann, Susanne, Niesen, Andreas, Schönberger, Johann, Barsegian, Vahé, Liepe, Knut, Mottaghy, Felix M., Guan, Rongjin, Pinkert, Joerg, Sandström, Per, Herrmann, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478815/
https://www.ncbi.nlm.nih.gov/pubmed/37385670
http://dx.doi.org/10.2967/jnumed.123.265557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478815/
https://www.ncbi.nlm.nih.gov/pubmed/37385670
http://dx.doi.org/10.2967/jnumed.123.265557

Ejemplares similares